MedTrace Logo

A Trial of CRD-4730 in HFrEF

NCT07750873 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 525

Last updated 2026-08-06

No results posted yet for this study

Summary

CRD-4730 is a calcium/calmodulin-dependent protein kinase II (CaMKII) inhibitor. The CALIBRATE-HF trial is a Phase 2, global, multi-center, randomized, double-blind, parallel-group, placebo-controlled trial. The trial will evaluate the efficacy, safety, and tolerability of CRD-4730 in addition to guideline directed medical therapy in participants with heart failure with reduced ejection fraction (HFrEF). Participants will be randomized to 1 of 4 study groups and receive investigational study drug or placebo twice daily (BID) for 24 weeks of treatment.

Conditions

  • Heart Failure With Reduced Ejection Fraction (HFrEF)

Interventions

DRUG

CRD-4730

Experimental, Dose A, B and C

DRUG

Placebo

Placebo

Sponsors & Collaborators

  • Cardurion Pharmaceuticals, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-07-15
Primary Completion
2028-09-30
Completion
2028-09-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07750873 on ClinicalTrials.gov